Form 4: Septerna CPO Exercises Options, Sells Shares

Septerna's Chief People Officer, Samira Shaikhly, exercised stock options and simultaneously sold an equal number of shares totaling over $1.98 million under a pre-arranged 10b5-1 plan.

Summary

• Chief People Officer Samira Shaikhly exercised 70,453 stock options of Septerna, Inc. common stock on March 2, 2026.
• The exercise prices for these options ranged from $1.55 to $2.76 per share.
• Concurrently, Shaikhly sold 70,453 shares of Septerna, Inc. common stock at weighted average prices ranging from $27.5052 to $28.1383 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 sales plan adopted on October 31, 2025.
• Following these transactions, Shaikhly beneficially owns 793 shares of common stock and 24,530 stock options.
• The 793 shares of common stock were acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves insider selling, the pre-planned nature via a 10b5-1 plan and the significant personal gain from long-held options are standard executive financial management, not necessarily a negative signal for the company's future.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planning and reducing concerns about opportunistic insider trading.
• The Chief People Officer realized a significant gain of approximately $1.85 million from exercising options and selling shares, demonstrating the value of the company's equity compensation program.

Negatives

• The sale of a substantial number of shares by a key executive could be perceived negatively by some investors, despite being pre-planned.
• The executive's direct beneficial ownership of common stock decreased significantly to 793 shares after the transactions.

Risks

• Insider selling, even when pre-planned, can sometimes be misinterpreted by the market as a lack of confidence in the company's future prospects, potentially leading to negative sentiment.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are a routine part of executive compensation and personal financial planning in the biotechnology or pharmaceutical industry, where equity grants are common. While the sale of shares by a Chief People Officer might draw attention, the pre-arranged nature of the transaction typically mitigates concerns about market timing or a negative signal regarding company fundamentals.

Stakeholder Impact

• Shareholders may observe a decrease in direct common stock ownership by a key executive, which could be interpreted in various ways, though the 10b5-1 plan mitigates negative signaling.
• The executive, Samira Shaikhly, benefits significantly from monetizing vested stock options, reflecting the value of her equity compensation.

Key Dates

Recommendation

The insider selling is part of a pre-arranged 10b5-1 plan, which is a routine financial management activity for executives. It does not necessarily signal a lack of confidence in the company's future. Therefore, it's prudent to hold the stock and monitor future company performance and other market indicators rather than reacting solely to this scheduled transaction.

Keywords

Septerna, SEPN, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation, Chief People Officer